Google Contact Lens

Last updated

Google Contact Lens was a smart contact lens project announced by Google on 16 January 2014. [1] The project aimed to assist people with diabetes by constantly measuring the glucose levels in their tears. [2] The project was being carried out by Verily and as of 2014 was being tested using prototypes. [1] On November 16, 2018, Verily announced it had discontinued the project. [3]

Contents

Design

The lens consists of a wireless chip and a miniaturized glucose sensor. A tiny pinhole in the lens allows for tear fluid to seep into the sensor to measure blood sugar levels. [4] Both of the sensors are embedded between two soft layers of lens material. The electronics lie outside of both the pupil and the iris so there is no damage to the eye. There is a wireless antenna inside of the contact that is thinner than a human's hair, which will act as a controller to communicate information to the wireless device. The controller will gather, read, and analyze data that will be sent to the external device via the antenna. Power will be drawn from the device which will communicate data via the wireless technology RFID. [5] Plans to add small LED lights that could warn the wearer by lighting up when the glucose levels have crossed above or below certain thresholds have been mentioned to be under consideration. [1] The performance of the contact lenses in windy environments and teary eyes is unknown. [4]

The prototypes being tested can generate a reading once per second.

Announcements

On January 16, 2014, Google announced that, for the past 18 months, [6] they had been working on a contact lens that could help people with diabetes by making it continually check their glucose levels. The idea was originally funded by the National Science Foundation [4] and was first brought to Microsoft. [5] The product was created by Brian Otis and Babak Parviz who were both members of the electrical engineering faculty at the University of Washington prior to working in Google's secret R&D organization, Google X. [5] Google noted in their official announcement that scientists have long looked into how certain body fluids can help track glucose levels easier, but as tears are hard to collect and study, using them was never really an option. They also mentioned that the project is currently being discussed with the FDA while still noting that there is a lot more work left to do before the product can be released for general usage, which is said to happen in five years at best, [6] and that they are looking for partners who would use the technology for the lens by developing apps that would make the measurements available to the wearers and their respective doctors. [1] The partners would also be expected to use this research and technology to develop advanced medical and vision devices for future generations. [4]

On July 15, 2014, Google announced a partnership with Novartis' Alcon unit to develop the glucose-sensing smart contact lens. [7]

On November 16, 2018, Verily announced it had discontinued the project because of the lack of correlation between tear glucose and blood glucose. [3]

Response

Endocrinologist Dr. Larry Levin commented the benefits of being able to offer his patients a pain-free alternative to either pricking their fingers or using a continuous glucose monitor. [8]

However, experts in the field [9] have cast doubt on the ability of the amount of glucose in tears (as measured by the contact lens) to correlate strongly with blood glucose of the user. Many reported studies show, at best, a weak correlation that would not meet accuracy requirements for glucose monitoring. [10] [11] [12] [13]

See also

Related Research Articles

<span class="mw-page-title-main">Insulin pump</span> Medical device to administer insulin

An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy. The device configuration may vary depending on design. A traditional pump includes:

Intensive insulin therapy or flexible insulin therapy is a therapeutic regimen for diabetes mellitus treatment. This newer approach contrasts with conventional insulin therapy. Rather than minimize the number of insulin injections per day, the intensive approach favors flexible meal times with variable carbohydrate as well as flexible physical activities. The trade-off is the increase from 2 or 3 injections per day to 4 or more injections per day, which was considered "intensive" relative to the older approach. In North America in 2004, many endocrinologists prefer the term "flexible insulin therapy" (FIT) to "intensive therapy" and use it to refer to any method of replacing insulin that attempts to mimic the pattern of small continuous basal insulin secretion of a working pancreas combined with larger insulin secretions at mealtimes. The semantic distinction reflects changing treatment.

The following is a glossary of diabetes which explains terms connected with diabetes.

<span class="mw-page-title-main">Blood glucose monitoring</span> Use of a glucose monitor for testing the concentration of glucose in the blood

Blood glucose monitoring is the use of a glucose meter for testing the concentration of glucose in the blood (glycemia). Particularly important in diabetes management, a blood glucose test is typically performed by piercing the skin to draw blood, then applying the blood to a chemically active disposable 'test-strip'. The other main option is continuous glucose monitoring (CGM). Different manufacturers use different technology, but most systems measure an electrical characteristic and use this to determine the glucose level in the blood. Skin-prick methods measure capillary blood glucose, whereas CGM correlates interstitial fluid glucose level to blood glucose level. Measurements may occur after fasting or at random nonfasting intervals, each of which informs diagnosis or monitoring in different ways.

<span class="mw-page-title-main">Blood sugar level</span> Concentration of glucose present in the blood (Glycaemia)

The blood sugar level, blood sugar concentration, blood glucose level, or glycemia, is the measure of glucose concentrated in the blood. The body tightly regulates blood glucose levels as a part of metabolic homeostasis.

Glycated hemoglobin is a form of hemoglobin (Hb) that is chemically linked to a sugar. Most monosaccharides, including glucose, galactose and fructose, spontaneously bond with hemoglobin when present in the bloodstream. However, glucose is less likely to do so than galactose and fructose, which may explain why glucose is used as the primary metabolic fuel in humans.

<span class="mw-page-title-main">Glucose meter</span> Medical device for determining the concentration of glucose in the blood

A glucose meter, also referred to as a "glucometer", is a medical device for determining the approximate concentration of glucose in the blood. It can also be a strip of glucose paper dipped into a substance and measured to the glucose chart. It is a key element of glucose testing, including home blood glucose monitoring (HBGM) performed by people with diabetes mellitus or hypoglycemia. A small drop of blood, obtained from slightly piercing a fingertip with a lancet, is placed on a disposable test strip that the meter reads and uses to calculate the blood glucose level. The meter then displays the level in units of mg/dL or mmol/L.

The term diabetes includes several different metabolic disorders that all, if left untreated, result in abnormally high concentrations of a sugar called glucose in the blood. Diabetes mellitus type 1 results when the pancreas no longer produces significant amounts of the hormone insulin, usually owing to the autoimmune destruction of the insulin-producing beta cells of the pancreas. Diabetes mellitus type 2, in contrast, is now thought to result from autoimmune attacks on the pancreas and/or insulin resistance. The pancreas of a person with type 2 diabetes may be producing normal or even abnormally large amounts of insulin. Other forms of diabetes mellitus, such as the various forms of maturity-onset diabetes of the young, may represent some combination of insufficient insulin production and insulin resistance. Some degree of insulin resistance may also be present in a person with type 1 diabetes.

Automated insulin delivery systems are automated systems designed to assist people with insulin-requiring diabetes, by automatically adjusting insulin delivery in response to blood glucose levels. Currently available systems can only deliver a single hormone—insulin. Other systems currently in development aim to improve on current systems by adding one or more additional hormones that can be delivered as needed, providing something closer to the endocrine functionality of the pancreas.

Noninvasive glucose monitoring (NIGM) is the measurement of blood glucose levels, required by people with diabetes to prevent both chronic and acute complications from the disease, without drawing blood, puncturing the skin, or causing pain or trauma. The search for a successful technique began about 1975 and has continued to the present without a clinically or commercially viable product.

<span class="mw-page-title-main">Minimed Paradigm</span> Insulin pumps

MiniMed Paradigm is a series of insulin pumps manufactured by Medtronic for patients with diabetes mellitus. The pump operates with a single AAA battery and uses a piston-plunger pump to infuse a programmed amount of insulin into the patient through a length of tubing. The Paradigm uses a one-way wireless radio frequency link to receive blood sugar measurements from select glucose meters. The Paradigm RT series adds the ability to receive data from a mated continuous blood-glucose monitor. Although the pump can use these measurements to assist in calculating a dose of insulin, no actual change in insulin delivery occurs without manual user-intervention.

<span class="mw-page-title-main">Wearable technology</span> Clothing and accessories incorporating computer and advanced electronic technologies

Wearable technology is any technology that is designed to be used while worn. Common types of wearable technology include smartwatches and smartglasses. Wearable electronic devices are often close to or on the surface of the skin, where they detect, analyze, and transmit information such as vital signs, and/or ambient data and which allow in some cases immediate biofeedback to the wearer.

<span class="mw-page-title-main">1,5-Anhydroglucitol</span> Chemical compound

1,5-Anhydroglucitol, also known as 1,5-AG, is a naturally occurring monosaccharide found in nearly all foods. Blood concentrations of 1,5-anhydroglucitol decrease during times of hyperglycemia above 180 mg/dL, and return to normal levels after approximately 2 weeks in the absence of hyperglycemia. As a result, it can be used for people with either type-1 or type-2 diabetes mellitus to identify glycemic variability or a history of high blood glucose even if current glycemic measurements such as hemoglobin A1c (HbA1c) and blood glucose monitoring have near normal values. Despite this possible use and its approval by the FDA, 1,5-AG tests are rarely ordered. There is some data suggesting that 1,5-AG values are useful to fill the gap and offer complementary information to HbA1c and fructosamine tests.

DexCom, Inc. is a company that develops, manufactures, produces, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has manufacturing facilities in Mesa, Arizona and Batu Kawan, Malaysia.

Wireless health is the integration of wireless technology into traditional medicine, such as diagnosis, monitoring and treatment of illness, as well as other tools that can help individuals improve their personal health and wellbeing. Wireless health differs from mHealth in that wireless health solutions will not always be mobile and mobile health solutions will not always be wirelessly enabled. Mobile broadband connectivity is useful in reaching new patients in remote areas while improving productivity and convenience through data transmission.

<span class="mw-page-title-main">Monitoring (medicine)</span> Observation of a disease, condition or one or several medical parameters over time

In medicine, monitoring is the observation of a disease, condition or one or several medical parameters over time.

<span class="mw-page-title-main">Verily</span> Life sciences research organization

Verily Life Sciences, also known as Verily, is Alphabet Inc.'s research organization devoted to the study of life sciences. The organization was formerly a division of Google X, until August 10, 2015, when Sergey Brin announced that the organization would become an independent subsidiary of Alphabet Inc. with restructuring completed on October 2, 2015. On December 7, 2015, Google Life Sciences was renamed Verily.

GlySens, a biomedical technology company, is a privately owned corporation developing a long term internal continuous glucose monitor in order to effectively manage and observe glucose levels in real time. The GlySens ICGM system is the world's first surgically implanted continuous glucose monitoring system to demonstrate an 18-month performance in a preclinical setting. GlySens Incorporated was founded in 1998 by David A. Gough and Joseph Lucisano, a bioengineering graduate at the University of California, San Diego. The implanted continuous glucose monitoring system uses an internal sensor equipped with electrochemical detectors to measure glucose readings via a chemical reaction between enzymes and oxygen.

<span class="mw-page-title-main">Continuous glucose monitor</span> Blood glucose monitoring device

A continuous glucose monitor (CGM) is a device used for monitoring blood glucose on a continual basis by insulin-requiring people with diabetes, e.g. people with type I, type II diabetes or other types of diabetes. A continuous glucose monitor consists of three parts: a small electrode placed under the skin, a transmitter sending readings at regular intervals, and a separate receiver. Currently approved CGMs use an enzymatic technology which reacts with glucose molecules in the interstitial fluid generating an electric current. This electric current is then relayed from a transmitter attached to the sensor out to a reader which displays the data to the patient.

Nemaura Medical is a UK based Medical Technology company developing a wireless non-invasive blood glucose monitoring system called SugarBeAT.

References

  1. 1 2 3 4 Brian Otis; Babak Parviz (16 January 2014). "Introducing our smart contact lens project". Google Official Blog. Retrieved 17 January 2014.
  2. ↑ NM Farandos; AK Yetisen; MJ Monteiro; CR Lowe; SH Yun (2014). "Contact Lens Sensors in Ocular Diagnostics". Advanced Healthcare Materials. 4 (6): 792–810. doi:10.1002/adhm.201400504. PMID   25400274. S2CID   35508652.
  3. 1 2 Brian Otis (16 November 2018). "Update on our Smart Lens program with Alcon". Verily Blog. Retrieved 21 November 2018.
  4. 1 2 3 4 Doyle, Maria (12 February 2014). "Google Contacts Will Help Diabetics Monitor Blood Sugar Via Tears". Forbes. Retrieved 20 March 2014.
  5. 1 2 3 "Google contact lens could help diabetics track glucose". CBC News. 17 January 2014. Retrieved 20 March 2014.
  6. 1 2 "Google contact lens could be option for diabetics". The Washington Post. 17 January 2014. Archived from the original on 17 January 2014. Retrieved 17 January 2014.
  7. ↑ Scott, Mark (15 July 2014). "Novartis Joins With Google to Develop Contact Lens That Monitors Blood Sugar". New York Times. Retrieved 21 November 2018.
  8. ↑ "Google announces 'smart' contact lenses that monitor glucose levels". Fox News. 16 January 2014. Retrieved 17 January 2014.
  9. ↑ Piller, Charles (2016-06-06). "Google misfires as it aims to turn science fiction into reality". Stat .
  10. ↑ Baca, Justin (2007). "Mass Spectral Determination of Fasting Tear Glucose Concentrations in Nondiabetic Volunteers". Clinical Chemistry. 53 (7): 1370–. doi: 10.1373/clinchem.2006.078543 . PMID   17495022.
  11. ↑ Zhang, Jin (January 2011). "Noninvasive Diagnostic Devices for Diabetes through Measuring Tear Glucose". Journal of Diabetes Science and Technology. 5 (1): 166–172. doi:10.1177/193229681100500123. PMC   3045221 . PMID   21303640.
  12. ↑ BACA, Justin (2007). "Tear Glucose Analysis for the Noninvasive Detection and Monitoring of Diabetes Mellitus". The Ocular Surface. 5 (4): 280–293. doi:10.1016/s1542-0124(12)70094-0. PMID   17938838.
  13. ↑ Smith, John (2015). "The Pursuit of Noninvasive Glucose: "Hunting the Deceitful Turkey"" (PDF).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.